{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:58:11Z","timestamp":1793051891387,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.exer.2021.108622","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T11:42:42Z","timestamp":1621424562000},"page":"108622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model"],"prefix":"10.1016","volume":"208","author":[{"given":"Narsis","family":"Daftarian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolbanin","family":"Baigy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhgan Rezaei","family":"Kanavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Balagholi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Afsar Aski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrooz","family":"Moghaddasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Nourinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1459-6752","authenticated-orcid":false,"given":"Seyed-Hossein","family":"Abtahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ahmadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.exer.2021.108622_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nprot.2007.4","article-title":"In vivo models of proliferative vitreoretinopathy","volume":"2","author":"Agrawal","year":"2007","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.exer.2021.108622_bib2","first-page":"134","article-title":"Retinal pigment epithelium culture;a potential source of retinal stem cells","volume":"4","author":"Akrami","year":"2009","journal-title":"J. Ophthalmic Vis. Res."},{"issue":"3","key":"10.1016\/j.exer.2021.108622_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00417290","article-title":"Experimental Fibroplasia in the rabbit vitreous. Retinal detachment induced by autologous fibroblasts","volume":"199","author":"Algvere","year":"1976","journal-title":"Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1167\/iovs.06-0928","article-title":"N-cadherin expression in a rat model of retinal detachment and reattachment","volume":"48","author":"Chen","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108622_bib5","first-page":"1010","article-title":"Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19","volume":"18","author":"Choi","year":"2012","journal-title":"Mol. Vis."},{"issue":"2","key":"10.1016\/j.exer.2021.108622_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.eye.6702169","article-title":"Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy","volume":"21","author":"Cui","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.exer.2021.108622_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.exer.2019.04.027","article-title":"Effects of intravitreal connective tissue growth factor neutralizing antibody on choroidal neovascular membrane-associated subretinal fibrosis","volume":"184","author":"Daftarian","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"24","key":"10.1016\/j.exer.2021.108622_bib8","doi-asserted-by":"crossref","first-page":"8454","DOI":"10.1128\/MCB.00821-07","volume":"27","author":"Dean","year":"2007","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.exer.2021.108622_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/eye.2014.21","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy","volume":"28","author":"Ghasemi Falavarjani","year":"2014","journal-title":"Eye"},{"issue":"39","key":"10.1016\/j.exer.2021.108622_bib10","doi-asserted-by":"crossref","first-page":"36288","DOI":"10.1074\/jbc.M201674200","article-title":"Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165","volume":"277","author":"Hashimoto","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.exer.2021.108622_bib11","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1167\/iovs.07-1302","article-title":"Connective tissue growth factor as a mediator of intraocular fibrosis","volume":"49","author":"He","year":"2008","journal-title":"Invest. Opthalmol. Visual Sci."},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF02150154","article-title":"Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye","volume":"225","author":"Hida","year":"1987","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.eye.6700190","article-title":"Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy","volume":"16","author":"Hinton","year":"2002","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000488492","article-title":"Animal models of proliferative vitreoretinopathy and their use in pharmaceutical investigations","volume":"60","author":"Hou","year":"2018","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2021.108622_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2015.09.029","article-title":"Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment","volume":"161","author":"Hsu","year":"2016","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.exer.2021.108622_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1096\/fj.01-0332fje","article-title":"Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis","volume":"16","author":"Inoki","year":"2002","journal-title":"Faseb. J."},{"issue":"1","key":"10.1016\/j.exer.2021.108622_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/db06-0581","article-title":"Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor","volume":"56","author":"Kita","year":"2007","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.exer.2021.108622_bib17","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2337\/db06-1644","article-title":"Functional characteristics of connective tissue growth factor on vitreoretinal cells","volume":"56","author":"Kita","year":"2007","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.exer.2021.108622_bib18","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archopht.124.10.1457","article-title":"Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye","volume":"124","author":"Kuiper","year":"2006","journal-title":"Arch. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9394(75)90390-6","article-title":"Glial cell proliferation in retinal detachment (massive periretinal proliferation)","volume":"80","author":"Laqua","year":"1975","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.exer.2021.108622_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9394(75)90862-4","article-title":"Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation)","volume":"80","author":"Machemer","year":"1975","journal-title":"Am. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.exer.2021.108622_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bjo.79.10.874","article-title":"Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease","volume":"79","author":"Mietz","year":"1995","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108622_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/269787","article-title":"Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid","author":"Morescalchi","year":"2013","journal-title":"Mediat. Inflamm."},{"issue":"8","key":"10.1016\/j.exer.2021.108622_bib23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/02713683.2017.1297996","article-title":"Ocular safety of intravitreal connective tissue growth factor neutralizing antibody","volume":"42","author":"Motevasseli","year":"2017","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2021.108622_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/815937","article-title":"Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside","author":"Moysidis","year":"2012","journal-title":"Mediat. Inflamm."},{"issue":"8","key":"10.1016\/j.exer.2021.108622_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/bem.22154","article-title":"The effects of electromagnetic fields on cultured human retinal pigment epithelial cells","volume":"39","author":"Nasrabadi","year":"2018","journal-title":"Bioelectromagnetics"},{"issue":"6","key":"10.1016\/j.exer.2021.108622_bib26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9394(02)01406-X","article-title":"Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy","volume":"133","author":"Ogata","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108622_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2021.108622_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.preteyeres.2013.12.006","article-title":"Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?","volume":"40","author":"Pennock","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"issue":"5","key":"10.1016\/j.exer.2021.108622_bib29","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.ajpath.2013.01.052","article-title":"Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease","volume":"182","author":"Pennock","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.exer.2021.108622_bib30","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.ajpath.2011.08.043","article-title":"A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy","volume":"179","author":"Pennock","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.exer.2021.108622_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0003-2697(77)90043-4","article-title":"A simplification of the protein assay method of Lowry et al. which is more generally applicable","volume":"83","author":"Peterson","year":"1977","journal-title":"Anal. Biochem."},{"issue":"5","key":"10.1016\/j.exer.2021.108622_bib32","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.exer.2021.108622_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.matbio.2018.03.007","article-title":"Connective tissue growth factor (CTGF) from basics to clinics","volume":"68\u201369","author":"Ramazani","year":"2018","journal-title":"Matrix Biol."},{"issue":"7","key":"10.1016\/j.exer.2021.108622_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.exer.2021.108622_bib35","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/archopht.1976.03910040390014","article-title":"Vitreous membranes: a light and electron microscopical study","volume":"94","author":"Smith","year":"1976","journal-title":"Arch. Ophthalmol."},{"issue":"5","key":"10.1016\/j.exer.2021.108622_bib36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/jop.2000.16.463","article-title":"Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment","volume":"16","author":"Su","year":"2000","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"issue":"3","key":"10.1016\/j.exer.2021.108622_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/2008-322X.188390","article-title":"Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study","volume":"11","author":"Tousi","year":"2016","journal-title":"J. Ophthalmic Vis. Res."},{"issue":"3","key":"10.1016\/j.exer.2021.108622_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(77)90684-5","article-title":"Glial cell proliferation in human retinal detachment with massive periretinal proliferation","volume":"84","author":"Van Horn","year":"1977","journal-title":"Am. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib39","first-page":"192","article-title":"Platelet rich plasma: myth or reality?","volume":"1","author":"Wang","year":"2007","journal-title":"Eur. J. Dermatol."},{"issue":"5","key":"10.1016\/j.exer.2021.108622_bib40","first-page":"480","article-title":"Filtering bleb area and intraocular pressure following subconjunctival injection of CTGF antibody after glaucoma filtration surgery in rabbits","volume":"4","author":"Wang","year":"2011","journal-title":"Int. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.exer.2021.108622_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0008-4182(02)80112-0","article-title":"Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells","volume":"37","author":"Wong","year":"2002","journal-title":"Can. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.exer.2021.108622_bib42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.17305\/bjbms.2010.2686","article-title":"An immunohistochemical analysis of a rat model of proliferative vitreoretinopathy and a comparison of the expression of TGF-beta and PDGF among the induction methods","volume":"10","author":"Zheng","year":"2010","journal-title":"Bosn. J. Basic Med. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:12:08Z","timestamp":1757999528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483521001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":43,"alternative-id":["S0014483521001883"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2021.108622","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2021.108622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108622"}}